Status:

COMPLETED

Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

URC-CIC Paris Descartes Necker Cochin

Conditions:

MPA

PAN or EGPA With FFS=0

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

To determine whether a combination of corticosteroids and azathioprine can achieve a higher remission rate and a lower subsequent relapse rate in patients with newly-diagnosed microscopic polyangiitis...

Detailed Description

Patients with new diagnosis of 1) microscopic polyangiitis, polyarteritis nodosa or eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome) and 2) without any factor of poor prognosis a...

Eligibility Criteria

Inclusion

  • male or female patients
  • aged over 18 years
  • new diagnosis of microscopic polyangiitis, polyarteritis nodosa or eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome), satisfying ACR 1990 and/or Chapel Hill Nomenclature criteria (positive biopsy is not mandatory providing those criteria are fulfilled)
  • with no factor of poor prognosis according to the French five factors score (FFS=0)
  • at diagnosis or within the first 21 days following initiation of corticosteroids
  • signed information and consent form
  • patients covered by Health Insurance
  • having had a baseline physical examination

Exclusion

  • patients with microscopic polyangiitis, polyarteritis nodosa or eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome) with one or more factor(s) of poor prognosis according to the French five factors score (FFS ≥ 1)
  • patients with polyarteritis nodosa with ANCA, not satisfying the criteria for microscopic polyangiitis
  • patients with clinically overt alveolar hemorrhage or respiratory distress syndrome
  • patient treated with corticosteroids for more than 15 days or already receiving another immunosuppressant
  • relapsing vasculitis
  • other vasculitis, especially secondary vasculitides
  • vasculitis secondary or associated with a viral infection, such as hepatitis B or C virus, or HIV
  • malignancy
  • pregnancy and breast feeding,women of child-bearing age not willing or with contra-indication to receive contraception
  • contra-indication to any of the study agents
  • need to continue allopurinol for those patients taking allopurinol
  • consent deny or inability to receive information and give consent
  • participation in another concomitant therapeutic trial
  • no affiliation to any of the general French health care system

Key Trial Info

Start Date :

May 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2015

Estimated Enrollment :

114 Patients enrolled

Trial Details

Trial ID

NCT00647166

Start Date

May 1 2008

End Date

April 1 2015

Last Update

September 12 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hopital Cochin Pôle de Médecine UF Médecine Interne

Paris, France, 75014